More states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
As the evidence grows regarding the role that obesity plays in many illnesses, more states are telling HMOs and other health insurers to pick up the tab for pharmaceuticals and other forms of obesity treatment.
According to StateLine,⢠Newtown, PA-based Scott-Levin's tracking system for government legislation and regulation, recent laws have taken effect in:
•Â Georgia, where the governor signed the Morbid Obesity Anti-Discrimination Act, which requires insurers to provide major medical benefits for treatment of morbid obesity.
•Â Indiana, where the governor signed a bill to require health insurers and HMOs to provide coverage for morbid obesity.
•Â Virginia, where the governor signed a bill to require coverage of gastric bypass surgery and "other recognized methods."
According to Scott-Levin, these measures represent just the beginning of this trend. In all, 26 states have recently proposed legislation addressing obesity-related issues.
The legislation is diverse. Some bills would establish commissions to study obesity and its health consequences. Others would regulate existing prescription and over-the-counter therapies for weight loss.
Underlying all this activity is the goal of state health policy-makers to better understand the true cost of obesity. PR
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.